Globus Medical (NYSE:GMED) Issues FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 4.400-4.50 for the period, compared to the consensus EPS estimate of 4.070. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

Analyst Ratings Changes

Several analysts have recently weighed in on GMED shares. Truist Financial set a $115.00 target price on Globus Medical in a research report on Wednesday. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th. Morgan Stanley raised their target price on shares of Globus Medical from $70.00 to $100.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Bank of America upgraded Globus Medical from a “neutral” rating to a “buy” rating and boosted their price target for the company from $65.00 to $91.00 in a report on Friday, November 7th. Finally, Wall Street Zen raised Globus Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Globus Medical has an average rating of “Moderate Buy” and a consensus target price of $104.36.

Globus Medical Price Performance

Globus Medical stock traded down $1.32 during trading hours on Friday, hitting $95.39. 1,205,994 shares of the stock traded hands, compared to its average volume of 1,225,530. Globus Medical has a 1 year low of $51.79 and a 1 year high of $101.40. The firm’s 50 day moving average price is $90.69 and its 200-day moving average price is $76.38. The stock has a market capitalization of $12.77 billion, a price-to-earnings ratio of 24.21, a P/E/G ratio of 2.24 and a beta of 1.06.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.22. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The company had revenue of $826.42 million for the quarter, compared to the consensus estimate of $803.29 million. During the same period last year, the firm earned $0.84 EPS. The firm’s revenue for the quarter was up 25.7% compared to the same quarter last year. Research analysts forecast that Globus Medical will post 3.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Globus Medical

In other news, CFO Kyle Kline sold 3,594 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $363,353.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 54,136 shares of company stock valued at $5,001,033. Company insiders own 18.51% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds have recently made changes to their positions in the stock. Advisory Services Network LLC acquired a new position in shares of Globus Medical during the third quarter worth about $26,000. EverSource Wealth Advisors LLC grew its position in Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the last quarter. Parallel Advisors LLC increased its position in Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares during the period. Headlands Technologies LLC grew its position in Globus Medical by 485.4% in the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after buying an additional 631 shares during the last quarter. Finally, Hollencrest Capital Management acquired a new position in shares of Globus Medical during the fourth quarter worth about $51,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.